Cleveland Biolabs (CBLI) 3.20 $CBLI Cleveland BioLabs

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 8:00 PM

Cleveland Biolabs (CBLI) 3.20 $CBLI

Cleveland BioLabs Announces Acceptance of Entolimod Phase 1 Study Findings for Poster Presentation at ASCO
Marketwired - Wed Apr 22, 8:13AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that findings from a Phase 1 clinical study of entolimod (previously known as CBLB502) have been accepted for poster presentation at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), which will be held from May 29 - June 2 in Chicago, Illinois.
CBLI: 3.20 (+0.01)

Where Are The Investors Headed: Complementary Research on Clovis Oncology, DBV Technologies, Cleveland BioLabs, Arrowhead Research and Athenahealth
PR Newswire - Fri Apr 17, 7:25AM CDT
Editor Note: For more information about this release, please scroll to bottom.
DBVT: 25.66 (-0.01), ARWR: 6.87 (+0.13), CLVS: 85.04 (-1.36), CBLI: 3.20 (+0.01), ATHN: 120.16 (-1.35)

Cleveland BioLabs Receives Funding Recommendation From Department of Defense for Additional Development Proposal for Entolimod (CBLB502) as a Medical Radiation Countermeasure
Marketwired - Tue Apr 14, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company received notice that a second proposal application to support further development of entolimod as a medical radiation countermeasure has been recommended for funding, subject to negotiations, by the Department of Defense (DoD) office of Congressionally Directed Medical Research Programs (CDMRP). This award is subject to successful negotiations and availability of funds.
CBLI: 3.20 (+0.01)

Cleveland BioLabs expects new composition of matter patent for CBLB612 in the US
M2 - Fri Apr 03, 6:38AM CDT
Biopharmaceutical company Cleveland BioLabs (NASDAQ:CBLI) disclosed on Thursday the allowance of a US patent application that covers composition of matter for CBLB612, an investigational drug in development for mobilisation of hematopoietic stem cells (HSCs) and for the prevention of chemotherapy-induced myelosuppression.
CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612
Marketwired - Thu Apr 02, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of a U.S. patent application, to issue as U.S. Patent No. 9,006,183, covering composition of matter for CBLB612, an investigational drug in development for mobilization of hematopoietic stem cells (HSCs) and for the prevention of chemotherapy-induced myelosuppression.
CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation
Marketwired - Mon Mar 16, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a maximally tolerated dose has been reached and that dosing has been completed in a Phase 1 healthy subject study of CBLB612, an investigational drug in development for mobilization of hematopoietic stem cells (HSCs) and for the prevention of chemotherapy-induced myelosuppression.
CBLI: 3.20 (+0.01)

Cleveland BioLabs: A Reverse Split Low Floater With Catalysts
Jonathan Faison - at Seeking Alpha - Wed Mar 11, 1:41PM CDT

CBLI: 3.20 (+0.01), LPTN: 2.26 (unch)

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutic Pipeline Market Review H1 2015 Available at LifeScienceIndustryResearch.com
PRWeb - Tue Mar 10, 2:01PM CDT
The report "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Radiation Toxicity. Radiation Toxicity is an acute illness caused by a dose greater than 50 rads of penetrating radiation to most or all of the body in a short time, usually a matter of minutes. Common exposures to low-dose radiation, such as X-ray or CT examinations, don't cause radiation sickness. The symptoms are Nausea and vomiting, Diarrhea, Headache, Fever, Dizziness and disorientation, Weakness, fatigue, Hair loss, bloody vomit and stools, infections, poor wound healing, low blood pressure. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.lifescienceindustryresearch.com/ra...-2015.html .
PSTI: 2.80 (-0.03), ONTX: 2.48 (-0.05), CBLI: 3.20 (+0.01)

Cleveland BioLabs and Incuron Announce Growth of Curaxin CBL0137 Patent Portfolio With U.S. Composition of Matter Patent
Marketwired - Mon Mar 02, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Incuron LLC, a joint venture between the CBLI and Bioprocess Capital Ventures, announce the issuance of a composition of matter patent for Curaxin CBL0137 in the U.S.
CBLI: 3.20 (+0.01)

Cleveland BioLabs' (CBLI) CEO Yakov Kogan on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 12:18PM CST

CBLI: 3.20 (+0.01)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 8:16AM CST

FRO: 2.77 (-0.20), EYES: 13.26 (-0.06), BIOC: 3.15 (+0.02), AXN: 1.77 (+0.01), SPWR: 34.74 (+0.28), WIN: 8.41 (+0.06), ROSE: 22.02 (-0.50), GENE: 4.88 (-0.05), FSLR: 63.88 (+0.77), CHGG: 8.04 (unch), APRI: 1.77 (-0.02), CBAY: 5.00 (-0.14), CYRN: 3.31 (+0.01), CBLI: 3.20 (+0.01), TCON: 12.48 (+0.09), CAPN: 6.99 (-0.29)

Cleveland BioLabs reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 6:33AM CST

CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces Receipt of Letter From NASDAQ Confirming Compliance With Minimum Bid Price Requirement
Marketwired - Wed Feb 18, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on February 12, 2015, the Company received a letter from The NASDAQ Stock Market stating that the Company has regained compliance with Listing Rule 5550(a)(2), maintenance of a minimum bid price of $1.00.
CBLI: 3.20 (+0.01)

Cleveland BioLabs to Report Fourth Quarter and Fiscal Year 2014 Financial Results on February 24
Marketwired - Tue Feb 17, 9:36AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on February 24, 2015, it will report its financial results for the fourth quarter and fiscal year ended December 31, 2014, and will host a conference call at 10:00 a.m. ET.
CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents
Marketwired - Wed Feb 11, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the issuance of several new patents for entolimod in the U.S. and other countries, further strengthening its patent position.
CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces Annual Meeting
Marketwired - Tue Feb 10, 6:01AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will hold its 2015 Annual Meeting of Stockholders on April 14, 2015 in Buffalo, NY for stockholders of record as of March 5, 2015. The Company will distribute proxy materials to all eligible stockholders.
CBLI: 3.20 (+0.01)

Cleveland BioLabs to Present at 2015 BIO CEO & Investor Conference
Marketwired - Thu Feb 05, 6:31AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2015 BIO CEO & Investor Conference, February 9-10, in New York, NY.
CBLI: 3.20 (+0.01)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 11:44AM CST

CALX: 8.48 (-0.07), NES: 3.52 (-0.15), RVP: 4.11 (+0.01), RL: 136.39 (+0.44), SR: 0.91 (-0.12), MWA: 10.26 (+0.27), OHGI: 1.74 (-0.01), GENE: 4.88 (-0.05), CALI: 1.38 (+0.01), WPRT: 4.39 (+0.01), RSYS: 2.10 (-0.02), EGLT: 10.34 (-0.27), PACB: 5.90 (-0.07), ACHN: 10.01 (-0.13), BBSI: 42.01 (-1.23), AVEO: 2.04 (+0.12), CBLI: 3.20 (+0.01), ENG: 1.67 (+0.02), PLNR: 6.07 (+0.44)

Cleveland BioLabs Announces $4.2 Million Financing
Marketwired - Wed Feb 04, 8:06AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has entered into definitive agreements with two institutional investors to purchase a total of $4.2 million of equity securities of the Company. The closing of the offering is expected to take place on or about February 6, 2015, subject to the satisfaction of customary closing conditions.
CBLI: 3.20 (+0.01), LTS: 3.56 (unch)

Cleveland BioLabs Announces Oncology Clinical Development Update for Entolimod
Marketwired - Thu Jan 29, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced updates on oncology clinical development of entolimod (previously known as CBLB502).
CBLI: 3.20 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

The Chemical Industry and EPA: A Broken System?

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...